SCHEMBL4606889

SCHEMBL4606889

CC(=O)OC[C@H]1OC(C)[C@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.57
CYP2D6 P10635 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TSHR P16473 1/20 0.56
NR3C1 P04150 1/20 0.56
FYN P06241 1/20 0.56
ADRA2A P08913 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
ADRA2B P18089 1/20 0.56
DRD4 P21917 1/20 0.56
DRD3 P35462 1/20 0.56
CA2 P00918 12/20 0.55
CA12 O43570 11/20 0.55
CA1 P00915 11/20 0.55
CA9 Q16790 8/20 0.55
PKM P14618 1/20 0.50
PTPN1 P18031 1/20 0.50
CA4 P22748 5/20 0.48
CA5A P35218 5/20 0.48
CA7 P43166 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15243619 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1
SCHEMBL13593687 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1
SCHEMBL16358235 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1
SCHEMBL14747304 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1
SCHEMBL6972799 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1
SCHEMBL14882448 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1
SCHEMBL22516447 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1
SCHEMBL22592286 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1
SCHEMBL20711502 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1
SCHEMBL13396025 1.00 THRB (0.57) THRBCYP2D6HSD17B10TSHRNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1305284-B1 PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES UNIV MICHIGAN STATE (US) 2008-11-12 EP claimed
EP-1305284-A4 PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES UNIV MICHIGAN STATE (US) 2005-08-03 EP claimed
EP-1305284-A1 PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES MICHIGAN STATE UNIVERSITY (US) 2003-05-02 EP claimed
US-6423867-B1 FROM TRI-O-ACETYL-D-ERYTHRO-4-PENTULOSONIC ACID ESTERS BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2002-07-23 US claimed
US-20020026071-A1 Process and intermediate compounds for the preparation of pyrrolidines BOARD OF TRUSTEES, OPERATING MICHIGAN STATE UNIVERSITY 2002-02-28 US claimed
US-20020026073-A1 Process and intermediate compounds for the preparation of pyrrolidines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2002-02-28 US claimed
US-20020026072-A1 Process and intermediate compounds for the preparation of pyrrolidines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2002-02-28 US claimed
US-20020026074-A1 Process and intermediate compounds for the preparation of pyrrolidines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERS 2002-02-28 US claimed
US-20020019542-A1 Process and intermediate compounds for the preparation of pyrrolidines MICHIGAN STATE UNIVERSITY BOARD OF TRUSTEES OPERATING 2002-02-14 US claimed
US-20020019561-A1 Process and intermediate compounds for the preparation of pyrrolidines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2002-02-14 US claimed
WO-2002010130-A1 PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES MICHIGAN STATE UNIVERSITY (US) 2002-02-07 WO claimed
US-11730752-B2 Use of NMN for the prevention and/or treatment of joint pain induced by physical activity, and corresponding compositions NUVAMID SA (CH) 2023-08-22 US disclosed
US-20230210746-A1 ANTI-AGING COSMETIC COMPOSITIONS COMPRISING NMN NUVAMID SA (CH) 2023-07-06 US disclosed
US-20230172959-A1 USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF A BACK PAIN AND CORRESPONDING COMPOSITIONS NUVAMID SA (CH) 2023-06-08 US disclosed
US-20230060438-A1 USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF JOINT PAIN INDUCED BY PHYSICAL ACTIVITY, AND CORRESPONDING COMPOSITIONS NUVAMID SA (CH) 2023-03-02 US disclosed
US-20020026071-A1 Process and intermediate compounds for the preparation of pyrrolidines BOARD OF TRUSTEES, OPERATING MICHIGAN STATE UNIVERSITY 2002-02-28 US disclosed
US-20020026073-A1 Process and intermediate compounds for the preparation of pyrrolidines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2002-02-28 US disclosed
US-20020019542-A1 Process and intermediate compounds for the preparation of pyrrolidines MICHIGAN STATE UNIVERSITY BOARD OF TRUSTEES OPERATING 2002-02-14 US disclosed
US-20020019561-A1 Process and intermediate compounds for the preparation of pyrrolidines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2002-02-14 US disclosed
WO-2002010130-A1 PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES MICHIGAN STATE UNIVERSITY (US) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230172959-A1 USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF A BACK PAIN AND CORRESPONDING COMPOSITIONS NNT, NAMPT, UTRN THRB 1104/4885CYP2D6 3978/4885HSD17B10 3411/4885
US-20230060438-A1 USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF JOINT PAIN INDUCED BY PHYSICAL ACTIVITY, AND CORRESPONDING COMPOSITIONS NNT, NAMPT, NMUR1 THRB 4002/4885CYP2D6 3544/4885HSD17B10 2773/4885
US-20020026073-A1 Process and intermediate compounds for the preparation of pyrrolidines UMPS, DUT, DPYD THRB 2246/4885CYP2D6 795/4885HSD17B10 3135/4885
US-20020026071-A1 Process and intermediate compounds for the preparation of pyrrolidines UMPS, DUT, DPYD THRB 2246/4885CYP2D6 795/4885HSD17B10 3135/4885
US-11730752-B2 Use of NMN for the prevention and/or treatment of joint pain induced by physical activity, and corresponding compositions NNT, NAMPT, NMUR1 THRB 4002/4885CYP2D6 3544/4885HSD17B10 2773/4885
US-20230210746-A1 ANTI-AGING COSMETIC COMPOSITIONS COMPRISING NMN NCL, POLN, CUTA THRB 4627/4885CYP2D6 4519/4885HSD17B10 1763/4885
US-20020019542-A1 Process and intermediate compounds for the preparation of pyrrolidines UMPS, DUT, DPYD THRB 2246/4885CYP2D6 795/4885HSD17B10 3135/4885
US-20020026074-A1 Process and intermediate compounds for the preparation of pyrrolidines UMPS, DUT, DPYD THRB 2246/4885CYP2D6 795/4885HSD17B10 3135/4885
US-20020026072-A1 Process and intermediate compounds for the preparation of pyrrolidines UMPS, DUT, DPYD THRB 2246/4885CYP2D6 795/4885HSD17B10 3135/4885
US-20020019561-A1 Process and intermediate compounds for the preparation of pyrrolidines UMPS, DUT, DPYD THRB 2246/4885CYP2D6 795/4885HSD17B10 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.